P294 Utilisation du liraglutide dans la « vraie vie » : il y a répondeurs et répondeurs

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings

“…However, clearly, for some patients a response corresponded to only slight decreases in weight and/or HbA1c [21], making the clinical significance of such results moot. In contrast, other studies have used definitions similar to those published in guidelines [22] or, more commonly, a long-term therapeutic goal of HbA1c < 7% [23,24].…”

“…A number of real-world studies looked at just one GLP1-RA or at GLP1-RAs as a class, or compared different GLP1-RAs [22,23,[29][30][31][32][33][34]. In one multicentre, observational, retrospective study, the long-term metabolic effects of exenatide BID (9 and 12 months in two cohorts) were analyzed in 299 patients with T2DM not responding to metformin and sulphonylurea at maximum dosages.…”